Manufacturing CAR T cells in the laboratory is expensive and time-consuming. An in vivo approach could get the powerful ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

Rui Tostoes, Chief Technology Officer at ImmuneBridge, shares how his team is redefining preclinical development and ...

Curious about mushroom supplements? Here's what they do, what the science says, and how to know if they're right for ...

There is no highly effective vaccine against tuberculosis (TB), which remains an infection of global concern. Charles ...

Ankyra Therapeutics is a biotech developing anchored immunotherapies aimed at enhancing the therapeutic window of ...

Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently ...

Verismo Therapeutics, a clinical-stage CAR T company pioneering the KIR-CAR platform, today provided additional details on ...

Zelluna ASA (the "Company") refers to the announcement on 24 May 2025 regarding a resolution by the Company's Board of ...

The fireside chat will be webcast live and can be accessed via a link in the Investors section of the Nurix website. The ...

Novel combination with efti has met the trial's primary endpoint of tumour hyalinization/fibrosis in the neoadjuvant setting ...

Senti Bio gets additional $1.0 million tranche from CIRM grant for advancing clinical development of SENTI-202: South San Francisco, California Friday, May 23, 2025, 16:00 Hrs [IS ...